[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341057-105":59,"doc-detail-341057-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oestrogen-receptor-positive-metastatic-eccrine-porocarcinoma-a-case-report-and-review-of-anti-oestrogen-therapy-in-rare-cancers","Oestrogen Receptor Positive Metastatic Eccrine Porocarcinoma - A Case Report and Review of Anti-Oestrogen Therapy in Rare Cancers","","Rare cancers remain therapeutically challenging due to limited clinical trial evidence, and metastatic eccrine porocarcinoma lacks a standard treatment approach. A reported case describes a patient with metastatic disease confirmed by bone biopsy, with pathology showing oestrogen receptor positivity. Treatment with letrozole and denosumab produced marked clinical and radiological improvement on bone scan within 7 months, and after more than 2 years there is no progression. The report supports anti-oestrogen therapy for ER-positive non-breast cancer guided by molecular drivers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oestrogen-receptor-positive-metastatic-eccrine-porocarcinoma-a-case-report-and-review-of-anti-oestrogen-therapy-in-rare-cancers/341057/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oestrogen-receptor-positive-metastatic-eccrine-porocarcinoma-a-case-report-and-review-of-anti-oestrogen-therapy-in-rare-cancers/341057.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is metastatic eccrine porocarcinoma difficult to treat?","Question",{"text":112,"@type":113},"Rare cancers overall have a high disease burden and are therapeutically challenging because clinical trials are limited. For metastatic eccrine porocarcinoma, there is no standard approach to management.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the diagnosis confirmed in the case report?",{"text":117,"@type":113},"Metastatic disease was confirmed on bone biopsy. Pathological analysis showed oestrogen receptor positivity.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment was used and what response was observed?",{"text":121,"@type":113},"The patient was started on the aromatase inhibitor letrozole and denosumab. A significant clinical and radiological response was seen on bone scan within 7 months, and the patient remained well with no evidence of progression after more than 2 years.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341057,1790225729,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Case Reports in Oncology  \n\n| Case Rep Oncol 2024;17:497–503 |  |\n| --- | --- |\n| DOI: 10.1159/000535328\u003Cbr>Received: March 21, 2023\u003Cbr>Accepted: November 16, 2023\u003Cbr>Published online: March 27, 2024 | © 2024 The Author(s) .\u003Cbr>Published by S. Karger AG, Basel [www.karger.com/cro](www.karger.com/cro) |\n\nThis article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ([http://www.karger.com/Services/OpenAccessLicense](http://www.karger.com/Services/OpenAccessLicense)). Usage and distribution for commercial purposes requires written permission.  \nCase Report  \nOestrogen Receptor Positive Metastatic Eccrine Porocarcinoma: A Case Report and Review of Anti-Oestrogen Therapy in Rare Cancers  \nAnita J. M. Kalakondaa, b Abhishek Mahajana Shien Chow a Anna C. Olsson-Brown a, c Joseph J. Saccoa, c  \naClatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK; bCRN North West Coast, NIHR, Liverpool, UK; c University of Liverpool, Liverpool, UK  \nKeywords  \nEccrine porocarcinoma · Case report · Oestrogen receptor positive · Aromatase inhibitors · Anti-oestrogen therapy  \nAbstract  \nIntroduction: Rare cancers, in aggregate, represent a significant burden of disease in oncology and remain therapeutically challenging to manage due to a lack of clinical trials. Eccrine porocarcinoma is a rare cutaneous sweat-gland malignancy for which there remains no standard approach to metastatic disease. Case Presentation: We describe a patient diagnosed with metastatic disease, confirmed on bone biopsy; pathological analysis further revealed this was oestrogen receptor positive. She was commenced on the aromatase inhibitor letrozole, and denosumab, and showed a significant clinical and radiological response on bone scan within 7 months. At the time of report, over 2 years since commencing letrozole, she remains well with no evidence of progression. Conclusion: Our experience adds to the literature suggesting anti-oestrogen therapy can have significant benefit in patients with ER-positive non-breast cancer and is in keeping with increasing interest in therapies agnostic to site of origin but guided by expression/mutation of oncogenic drivers.  \n© 2024 The Author(s) .  \nPublished by S. KargerAG, Basel  \nCorrespondence to:  \nAnita J. M. Kalakonda, [anita.kalakonda1](anita.kalakonda1@ nhs.net)[@](anita.kalakonda1@ nhs.net)[ nhs.net](anita.kalakonda1@ nhs.net)[ ](anita.kalakonda1@ nhs.net)Joseph J. Sacco, [joseph.sacco](joseph.sacco@ nhs.net)[@](joseph.sacco@ nhs.net)[ nhs.net](joseph.sacco@ nhs.net)  \nCase Reports in Oncology  \nCase Rep Oncol 2024;17:497–503 498  \n\n| DOI: 10.1159/000535328 | © 2024 The Author(s) . Published by S. Karger AG, Basel [www.karger.com/cro](www.karger.com/cro) |\n| --- | --- |\n\nKalakonda et al.: ER-Positive Eccrine Porocarcinoma  \nIntroduction  \nRare cancers are defined as neoplasms with an annual incidence rate of6 per 100,000 people or less; and together constitute around 24% of all cancer diagnoses in Europe [1]. With increasing understanding of the molecular and pathological features of cancers, there is a recognition that many more common cancers may need to be considered collections of similar but distinct malignancies. Rare cancer patients experience diagnostic delays and a reduced availability of therapies due to the lack of clinical trials to provide an evidence base foroncological management [1]. Eccrine porocarcinoma (EPC), a rare tumour of cutaneous sweat glands, makes up less than 0.01% of skin-related malignancies [2]. Surgical techniques such as wide-local excision and Moh’s micrographic surgery are employed in the initial management of EPC [2]. However, eccrine carcinoma carries a potential for recurrent and/or metastatic disease and therefore results in significant morbidity and mortality [3]. 10% of EPC cases are found to be metastatic at diagnosis, with 20% of cases reported to develop regional lymph node metastasis [2].  \nA variety of regimens have been reported; h","cbCainRk5pqTvQlv","https://ap.wps.com/l/cbCainRk5pqTvQlv","pdf",430357,"English","## Introduction\n## Case Presentation\n## Investigations","[{\"question\":\"Why is metastatic eccrine porocarcinoma difficult to treat?\",\"answer\":\"Rare cancers overall have a high disease burden and are therapeutically challenging because clinical trials are limited. For metastatic eccrine porocarcinoma, there is no standard approach to management.\"},{\"question\":\"How was the diagnosis confirmed in the case report?\",\"answer\":\"Metastatic disease was confirmed on bone biopsy. Pathological analysis showed oestrogen receptor positivity.\"},{\"question\":\"What treatment was used and what response was observed?\",\"answer\":\"The patient was started on the aromatase inhibitor letrozole and denosumab. A significant clinical and radiological response was seen on bone scan within 7 months, and the patient remained well with no evidence of progression after more than 2 years.\"}]","Oestrogen Receptor Positive Metastatic Eccrine Porocarcinoma - A Case Report and Review of Anti-Oestrogen Therapy in Rare Cancers | PDF",1790040110,18]